Ciraparantag (TFA)

• Description :

  Ciraparantag (PER977) TFA is a thrombin and factor Xa inhibitor. Ciraparantag TFA is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban[1][2][3][4].

• Product Name Alternative :

  PER977 (TFA)

• UNSPSC :

  12352005

• Target :

  Factor Xa; Thrombin

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/ciraparantag-tfa.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(NCCCN1CCN(CCCNC([C@@H](N)CCCNC(N)=N)=O)CC1)[C@@H](N)CCCNC(N)=N.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F

• Molecular Formula :

  C26H50F6N12O6

• Molecular Weight :

  740.74

• References & Citations :

  [1]Das A, et al. Novel antidotes for target specific oral anticoagulants. Exp Hematol Oncol. 2015 Sep 15;4:25.|[2]Gomez-Outes A, et al. Specific antidotes in development for reversal of novel anticoagulants: a review. Recent Pat Cardiovasc Drug Discov. 2014;9 (1) :2-10.|[3]Hu TY, et al. Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. Vasc Health Risk Manag. 2016 Feb 17;12:35-44.|[4]Honickel M, et al. The Reversal of Direct Oral Anticoagulants in Animal Models. Shock. 2017 Aug;48 (2) :144-158.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• CAS Number :

  [1438492-27-3]